TLR3 and hepatocellular carcinoma: TLR3 agonist Poly-ICLC (Hiltonol), which has been previously demonstrated to boost innate immune response in patients [62], was reported to impair the progression of hepatocellular carcinoma when combined with sorafenib, through the activation of NK and CD8+ T cells [63].